The CML patients in Shanghai received the treatment of HU, IFN-α with/without Ara-C, imatinib, HSCT, chemotherapy, and traditional Chinese medicine. This evidence concerns the gene IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive.